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Abstract
Introduction: Systemic sclerosis (SSc) is a connective tissue disorder characterized by endothelial cell injury,
autoimmunity and fibrosis. The following three fibrillin-1 alterations have been reported in SSc. (1) Fibrillin-1
microfibrils are disorganized in SSc dermis. (2) Fibrillin-1 microfibrils produced by SSc fibroblasts are unstable.
(3) Mutations in the FBN1 gene and anti-fibrillin-1 autoantibodies have been reported in SSc. Fibrillin-1 microfibrils,
which are abundantly produced by blood and lymphatic microvascular endothelial cells (B-MVECs and Ly-MVECs,
respectively), sequester in the extracellular matrix the latent form of the potent profibrotic cytokine transforming
growth factor b (TGF-b). In the present study, we evaluated the effects of SSc sera on the deposition of fibrillin-1
and microfibril-associated glycoprotein 1 (MAGP-1) and the expression of focal adhesion molecules by dermal
B-MVECs and Ly-MVECs.
Methods: Dermal B-MVECs and Ly-MVECs were challenged with sera from SSc patients who were treatment-naïve
or under cyclophosphamide (CYC) treatment and with sera from healthy controls. Fibrillin-1/MAGP-1 synthesis and
deposition and the expression of avb3 integrin/phosphorylated focal adhesion kinase and vinculin/actin were
evaluated by immunofluorescence and quantified by morphometric analysis.
Results: Fibrillin-1 and MAGP-1 colocalized in all experimental conditions, forming a honeycomb pattern in
B-MVECs and a dense mesh of short segments in Ly-MVECs. In B-MVECs, fibrillin-1/MAGP-1 production and avb3
integrin expression significantly decreased upon challenge with sera from naïve SSc patients compared with
healthy controls. Upon challenge of B-MVECs with sera from CYC-treated SSc patients, fibrillin-1/MAGP-1 and avb3
integrin levels were comparable to those of cells treated with healthy sera. Ly-MVECs challenged with SSc sera did
not differ from those treated with healthy control sera in the expression of any of the molecules assayed.
Conclusions: Because of the critical role of fibrillin-1 in sequestering the latent form of TGF-b in the extracellular
matrix, its decreased deposition by B-MVECs challenged with SSc sera might contribute to dermal fibrosis. In SSc,
CYC treatment might limit fibrosis through the maintenance of physiologic fibrillin-1 synthesis and deposition by
B-MVECs.
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Introduction
Fibrillins are large glycoproteins (approximately 350 kDa)
present in the extracellular matrix (ECM). In lymphatic
vessels, fibrillin microfibrils form filaments anchoring
lymphatic endothelial cells (ECs) to the surrounding elas-
tic fibers [1,2]. This structure modulates interstitial fluid
entry into the lymphatic vessels, contributing to the phy-
siologic tissue homeostasis [3]. Fibrillin microfibrils are
also present in the arterial wall to maintain the elasticity
which is usually lost in Marfan syndrome, where a fibril-
lin-1-encoding gene (FBN1) mutation fosters aortic dila-
tation and dissection [4,5]. During development, fibrillin
constitutes a scaffold for elastin deposition. It also
sequesters in the ECM signaling molecules, such as the
profibrotic cytokine transforming growth factor b (TGF-
b), which regulates ECM synthesis and remodeling [6].
Microfibril-associated glycoprotein 1 (MAGP-1) is a
small glycoprotein of 31 kDa that resides on microfibril
beads and colocalizes with virtually all fibrillin-1-contain-
ing microfibrils [7].
Fibrillin-1 is produced by different cell types [8-11],
including blood and lymphatic ECs [12,13]. Its deposition
differs in cultured bovine aortic and thoracic duct ECs.
Blood ECs deposit fibrillin-1 in a honeycomb pattern
with fibrillin-free spaces, whereas lymphatic ECs form a
thick, irregular network of fibrillin-1 in the underlying
ECM [12,13]. Blood and lymphatic microvascular ECs
(hereafter referred to as B-MVECs and Ly-MVECs,
respectively) isolated from human foreskin also deposit
fibrillin-1 and MAGP-1 in vitro [14]. Fibrillin-1 microfi-
brils form a wide-mesh honeycomb, leaving fibrillin-free
spaces that are gradually filled in by other microfibrils
in both B-MVEC and Ly-MVEC cultures. In some
Ly-MVECs, fibrillin-1 is initially deposited as uniformly
scattered short fibrillin strands [14].
Alterations in fibrillin-1 have been reported in patients
with systemic sclerosis (SSc, or scleroderma) and in the
tight skin 1 (Tsk1) mouse model [15,16]. A disorganized
deposition of fibrillin-1 has been observed in SSc skin [17].
Cultured dermal fibroblasts from SSc patients have been
found to produce abnormal fibrillin-1 microfibrils which
were unstable, less numerous and more susceptible to
proteolytic degradation [18,19]. Tsk1 mice have a duplica-
tion in the FBN1 gene which results in a larger protein
(450 kDa) that is more susceptible to proteolysis [20]. The
instability of fibrillin-1 may cause an uncontrolled release
of TGF-b, which is normally sequestered in the ECM as a
latent inactive molecule, with consequent activation of
fibroblasts and excessive collagen synthesis, ultimately
leading to tissue fibrosis [21]. Moreover, microfibril frag-
ments released in the ECM may reveal cryptic epitopes
that may become the targets of an immune response with
formation of anti-fibrillin-1 autoantibodies in SSc [22-24].
Associations of polymorphisms in the FBN1 gene and SSc
susceptibility have also been reported in some ethnic
groups with high prevalence of SSc (Choctaw American
Indians and Japanese) [25-27].
It has been reported that latent TGF-b can be activated
by interaction with avb3 and avb5 integrins that are over-
expressed in cultured SSc dermal fibroblasts [28,29]. In
particular, the avb3 integrin may contribute to the estab-
lishment of an autocrine TGF-b loop potentiating fibrosis.
Mutations in the arginine-glycine-aspartic acid (RGD)
fibrillin-1 domain, which mediates integrin binding, have
been found in the stiff skin syndrome, an autosomal domi-
nant congenital form of scleroderma [30]. In stiff skin syn-
drome, altered cell-matrix interactions parallel an
excessive microfibrillar deposition, altered elastogenesis
and increased TGF-b signaling in the dermis.
Because the endothelium is one of the principal targets
of SSc, we focused our attention on two physiologic
activities of ECs that may be of relevance in this disease:
fibrillin-1 deposition and focal adhesion molecule expres-
sion. We therefore evaluated the effect of sera from SSc
patients on the deposition of fibrillin-1 and MAGP-1 and
the expression of focal adhesion molecules by human
adult dermal B-MVECs and Ly-MVECs. We also investi-
gated the effect of the powerful immunosuppressant
cyclophosphamide (CYC) on the deposition of fibrillin-1
and the expression of focal adhesion molecules by dermal
B-MVECs and Ly-MVECs.
Materials and methods
Ethical approval
All SSc patients and control subjects signed an informed
consent form. The study was conducted in compliance
with the principles of the Declaration of Helsinki and was
approved by the local institutional review board at the
Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Patients and serum samples
Serum samples were obtained from a total of 21 consecu-
tive patients with SSc (17 women, 4 men) recruited from
the Division of Rheumatology, University of Florence.
Patients with symptoms overlapping with those of other
autoimmune, rheumatic and/or connective tissue dis-
eases were excluded from the study. Eight age- and sex-
matched healthy individuals were used as controls.
Patients were classified as having limited cutaneous SSc
(lSSc; n = 13) or diffuse cutaneous SSc (dSSc; n = 8)
according to the categorization described by LeRoy et al.
[31]. All SSc patients were clinically assessed as pre-
viously described [32]. Thirteen patients (eight with lSSc
and five with dSSc) were receiving monthly intravenous
infusions of CYC (dose range, 1 to 1.5 g/m2 for 12 to 18
months), and the other eight patients were not taking
any immunosuppressant or disease-modifying drugs.
Blood was drawn from CYC-treated patients 1 month
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after the previous infusion. The demographic, clinical and
serological characteristics of SSc patients are reported in
Table 1. Fresh venous blood samples from patients and
healthy controls were allowed to clot for 30 min before
centrifugation at 1,500 g for 15 min. Serum was collected
and stored in aliquots at -80°C until used.
Cells
Human adult dermal B-MVECs and Ly-MVECs were
obtained from Lonza (HMVEC-dBlAd and HMVEC-
dLyAd, respectively; Lonza, Milan, Italy). Cells were
seeded into 75-cm2 flasks in complete Endothelial Growth
Medium 2 (EGM-2) supplemented with the EGM-2-MV
BulletKit (Lonza). Once at confluence, cells were trypsi-
nized with a trypsin/ethylenediaminetetraacetic acid solu-
tion (Lonza), centrifuged, resuspended in medium with
EGM-2-MV and seeded onto gelatin-coated coverslips at a
density of 4.5 × 104 cells/coverslip. At confluence, all med-
ium was removed and cells were starved in endothelial
basal medium (EBM) for 2 h, then fed with fresh EBM
containing 15% of serum from lSSc or dSSc patients, naïve
or under pharmacological therapy with CYC, or from
healthy controls. Fibrillin-1 evaluation was performed on
cells at 2 days after confluence because it has been shown
that fibrillin-1 deposition in vitro increases with time in
culture [33]. The expression of focal adhesion molecules
and the actin cytoskeleton assembly were also evaluated at
the same time point.
Double-immunolabeling of fibrillin-1 and microfibril-
associated glycoprotein 1
After fixation in cold acetone for 7 min, cells were washed
in phosphate-buffered saline (PBS) and incubated for
40 min in 3% bovine serum albumin (BSA) in PBS to
block unspecific binding sites. The first immunolabeling
was performed by overnight incubation at 4°C with a poly-
clonal antibody to MAGP-1 (MFAP-2; Sigma-Aldrich,
Milan, Italy) diluted 1:25 in PBS containing 0.5% BSA fol-
lowed by incubation for 1 h with a goat anti-rabbit Alexa
Fluor 594-conjugated immunoglobulin G (IgG) antibody
(1:1,000 dilution in PBS with 1% BSA; Invitrogen, Milan,
Italy). Before the second immunolabeling, unspecific bind-
ing sites were again blocked. Cells were then incubated
for 2 h with a monoclonal antibody to fibrillin-1 (1:100
dilution in PBS with 0.5% BSA; Chemicon International/
Millipore, Milan, Italy). The reaction was revealed by incu-
bation for 1 h with goat anti-mouse Alexa Fluor 488-
conjugated IgG1 (1:1,000 dilution in PBS with 1% BSA;
Invitrogen). Nuclei were counterstained for 10 min with
4′,6-diamidino-2-phenylindole (DAPI, 1:1,000 dilution in
PBS; Sigma-Aldrich). After being washed, coverslips were
mounted on glass slides with DABCO mounting medium
(Sigma-Aldrich).
Double-immunolabeling of adhesion molecules
Cells were fixed for 7 min in 4% buffered paraformalde-
hyde, permeabilized for 10 min with 0.1% Triton X-100
in PBS, washed, and incubated for 30 min in PBS with
1% BSA to block unspecific binding sites. The latter buf-
fer was used for all subsequent dilutions. For double-
labeling with avb3 integrin and phosphorylated focal
adhesion kinase (FAK), the first labeling was performed
by overnight incubation at 4°C with a mouse monoclonal
antibody to human avb3 integrin (vitronectin receptor,
1:50 dilution; Chemicon International), followed by incu-
bation for 1 h with a goat anti-mouse antibody, Alexa
Fluor 488-conjugated IgG (1:1,000 dilution; Invitrogen).
After unspecific binding sites were blocked, cells were
washed and incubated for 2 h with a rabbit polyclonal
antibody to phosphorylated FAK (anti-FAK (phospho
Y397), 1:100 dilution; Abcam, Cambridge, UK). For dou-
ble-labeling with phalloidin and vinculin, the first label-
ing was performed with a 20-min incubation with Alexa
488 phalloidin (1:40 dilution; Invitrogen), followed by
block of unspecific binding sites and then by overnight
incubation with a monoclonal antibody to vinculin (1:100
dilution; Sigma-Aldrich). The reaction was revealed by
Table 1 Demographic and clinical characteristics of the
21 patients with systemic sclerosisa
Characteristics SSc patients (N = 21)
Mean age (±SD), yr 56.5 ± 12.1
Sex, n (%)
Male 4 (19.1)
Female 17 (80.9)
Disease subset, n (%)
lSSc 13 (61.9)
dSSc 8 (38.1)
Mean disease duration (±SD), yrb 7.7 ± 4.1
Autoantibody positivity, n (%)
ANA 21 (100)
Anti-Scl-70 7 (33.3)
ACA 10 (47.6)
Digital ulcers, n (%) 12 (57.1)
Nailfold capillaroscopy pattern, n (%)
Early 4 (19.0)
Active 8 (38.1)
Late 9 (42.9)
Mean skin score (±SD) 10.2 ± 6.3
ILD, n (%)c 11 (52.4)
CYC treatment, n (%) 13 (61.9)d
aACA, anticentromere antibodies; ANA, antinuclear antibodies; Anti-Scl-70,
anti-Scl-70 antibodies; CYC, cyclophosphamide; dSSc, diffuse cutaneous
systemic sclerosis; ILD, interstitial lung disease; lSSc, limited cutaneous
systemic sclerosis; SSc, systemic sclerosis. Except where indicated otherwise,
values are the number (%) of participants. bDisease duration was calculated
from the date of the first non-Raynaud’s symptom of SSc. cDetermined by
high-resolution computed tomography scan. dEight patients with lSSc and five
patients with dSSc.
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1-h incubation with goat anti-mouse Alexa Fluor 594-
conjugated IgG1 (1:1,000 dilution; Invitrogen). Cell nuclei
were counterstained with DAPI, and coverslips were
mounted with DABCO mounting medium.
Morphometric analysis
Coverslips with adhering cells were photographed in
randomly selected fields under a ×40 objective while
maintaining fixed exposure parameters. Fluorescence
was analyzed using the NIS-Elements D morphometric
software program (Nikon, Tokyo, Japan) on at least 35
photomicrographs/condition for fibrillin-1 and MAGP-1
and 15 photomicrographs/condition for focal adhesion
molecules. The amount of fluorescence was expressed
as sum density, which is the sum of individual optical
density (O.D.) of each pixel in the area being measured.
O.D. is evaluated according to the following formula:
O.D. = -log((pixel intensity value + 0.5)/62.5).
Statistical analysis
Data presented are means and standard errors of the
mean (SEM). Statistical analysis was performed using
Student’s t-test for independent groups. A P-value less
than 0.001 according to a two-tailed distribution was
considered statistically significant unless otherwise
specified.
Results
Morphologic evaluation of fibrillin-1 and microfibril-
associated glycoprotein 1 deposition by dermal B-MVECs
and Ly-MVECs
Fibrillin-1 and MAGP-1 colocalized in dermal B-MVECs
and Ly-MVECs in all experimental conditions tested
(Figures 1A and 2A) in accordance with previous
reports in the literature [7] and our previous results in
human foreskin microvascular ECs [14]. The deposition
pattern of the two proteins differed between B-MVECs
and Ly-MVECs, however. In B-MVECs, fibrillin-1
microfibrils formed a wide mesh with a honeycomb pat-
tern with fibrillin-1-free spaces in which cells were still
visible (Figure 1A). Thin strands of fibrillin-1 arising
from the honeycomb borders subdivided fibrillin-1-free
spaces into smaller ones, and the space between differ-
ent honeycombs was also filled by a thin network of
fibrillin-1 fibers. In Ly-MVECs, fibrillin-1 microfibrils
were deposited as short, thin strands forming a thick
mesh covering the surface (Figure 2A). Honeycombs
were rarely observed in Ly-MVEC cultures.
Quantitative analysis of fibrillin-1 and microfibril-
associated glycoprotein 1 deposition by dermal B-MVECs
and Ly-MVECs challenged with systemic sclerosis sera
In B-MVECs, the production and deposition of fibrillin-1
and MAGP-1 were significantly lower in cultures challenged
with sera from naïve SSc patients than in cultures challenged
with healthy control sera (P < 0.001) (Figure 1B). No signifi-
cant differences were observed between cells challenged
with lSSc and dSSc naïve sera (Figure 1B). Upon challenge
with sera from CYC-treated SSc patients, B-MVECs depos-
ited fibrillin-1/MAGP-1 at levels comparable to those of
cells treated with healthy control sera (Figure 1B). In parti-
cular, no significant difference in fibrillin-1/MAGP-1 deposi-
tion was found between B-MVECs stimulated with sera
from healthy controls and those stimulated with CYC-trea-
ted dSSc sera (Figure 1B). Fibrillin-1/MAGP-1 values upon
challenge with CYC-treated lSSc sera were even higher (P <
0.05) than those of healthy controls (Figure 1B). In Ly-
MVECs, there were no significant differences between cul-
tures challenged with sera from healthy controls, naïve SSc
patients and CYC-treated SSc patients (Figure 2B).
Quantitative analysis of avb3 integrin, phosphorylated
FAK, vinculin and actin expression by dermal B-MVECs
and Ly-MVECs challenged with systemic sclerosis sera
Both in B-MVECs and Ly-MVECs, avb3 integrin, phos-
phorylated FAK and vinculin were visible as small dots
distributed all over the cell surface. Actin filaments
stained by phalloidin were principally arranged in long
strands running parallel to cell borders (Figure 3).
In B-MVECs, the expression of avb3 integrin was sig-
nificantly lower in cells challenged with the serum of
naïve SSc patients than in healthy controls (P < 0.001)
(Figure 4A). No significant differences were observed
between cells challenged with lSSc and dSSc naïve sera
(Figure 4A). Upon challenging of B-MVECs with sera
from CYC-treated SSc patients, the levels of avb3 integ-
rin expression were similar to those in cells treated with
healthy control sera (Figure 4A). Moreover, the expres-
sion of avb3 integrin was higher in cells challenged with
sera of CYC-treated SSc patients compared with treat-
ment-naïve SSc patients (P < 0.001) (Figure 4A).
Vinculin expression was significantly higher in
B-MVECs challenged with sera of treatment-naïve dSSc
patients than in sera of healthy controls (P < 0.001)
(Figure 4B). We failed to detect any significant differ-
ence in phosphorylated FAK and actin expression
among the different experimental conditions (data not
shown). In Ly-MVECs, no significant differences could
be detected for any of the focal adhesion molecules
tested among the different experimental conditions
(data not shown).
Discussion
Our work shows for the first time that a reduced
deposition of fibrillin-1 and dysregulated expression of
focal adhesion molecules by dermal B-MVECs may have
an important role in SSc pathophysiology, and that the
beneficial effects of CYC treatment may be due in part
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to the normalization of cell-matrix interactions and
fibrillin-1 deposition by B-MVECs.
In the literature, there are controversial data on fibrillin
deposition in SSc. In the lower dermis of localized sclero-
derma and SSc, Fleischmajer et al. [17] described a mas-
sive deposition of 10-nm microfibrils interspersed among
collagen fibers. They suggested that the increase in fibrillin
deposition in the ECM might be the result of an abnormal
activation of dermal fibroblasts that leads to significant
accumulation of collagen and microfibrils. Other authors
have reported a decrease of the microfibrillar network in
biopsies from both clinically affected and unaffected dSSc
skin [36]. Data on fibrillin deposition by cultured SSc der-
mal fibroblasts are also controversial. Some authors have
Figure 1 Systemic sclerosis sera affect deposition of fibrillin-1 and microfibril-associated glycoprotein 1 by dermal blood
microvascular endothelial cells. Fibrillin-1 and microfibril-associated glycoprotein 1 (MAGP-1) deposition by dermal blood microvascular
endothelial cells (B-MVECs) was evaluated after challenge with systemic sclerosis (SSc) and healthy control (CTR) sera. (A) Representative
immunofluorescent images for fibrillin-1 (green) and MAGP-1 (red). The two molecules colocalize and are deposited in a honeycomb pattern,
with empty spaces in which endothelial cells are still visible. 4′,6-diamidino-2-phenylindole (DAPI)-stained nuclei are blue in merged images.
Original magnification, ×40. (B) Quantification of fibrillin-1 deposition by measurement of optical density in arbitrary units (a.u.). Data are means
± SEM. Fibrillin-1 deposition was significantly reduced in B-MVECs challenged with naïve SSc sera (all naïve SSc, naïve limited SSc (lSSc) and
naïve diffuse SSc (dSSc)) vs. healthy controls (**P < 0.001). Fibrillin-1 was significantly higher in cyclophosphamide (CYC)-treated lSSc than in
controls (*P < 0.05). No significant difference was found between all CYC-treated SSc and CYC-treated dSSc vs. healthy controls.
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found an increased production of fibrillin-1 in SSc fibro-
blasts [34,35], but other authors have found no difference
in the expression of fibrillin-1 between SSc fibroblasts
from involved and uninvolved skin and controls [36].
Another in vitro study reported a reduction in fibrillin
deposition by SSc fibroblasts from involved skin [18].
In the present study, we investigated for the first time
the possible contribution of dermal microvascular ECs to
fibrillin deposition abnormalities in SSc. It is well-known
that blood and lymphatic ECs synthesize and deposit
fibrillin-1 in the ECM and that the endothelium is one of
the earliest and most important targets in SSc pathogen-
esis [12-14,37]. In particular, we used dermal B-MVECs
and Ly-MVECs obtained from healthy individuals and
challenged them with SSc sera. The rationale for investi-
gating both B-MVECs and Ly-MVECs comes from the
recent findings that not only blood microvessels but also
lymphatic microvessels are affected in SSc [38-40].
Figure 2 Lack of effect of systemic sclerosis sera on deposition of fibrillin-1 and microfibril-associated glycoprotein 1 by dermal lymphatic
microvascular endothelial cells. Fibrillin-1 and microfibril-associated glycoprotein 1 (MAGP-1) deposition by dermal lymphatic microvascular
endothelial cells (Ly-MVECs) was evaluated after challenge with systemic sclerosis (SSc) and healthy control (CTR) sera. (A) Representative
immunofluorescent images for fibrillin-1 (green) and MAGP-1 (red). The two molecules colocalize and are deposited in thin, short strands, only rarely
forming honeycombs. 4′,6-diamidino-2-phenylindole (DAPI)-stained nuclei are blue in merged images. Original magnification, ×40. (B) Quantification
of fibrillin-1 deposition by measurement of optical density in arbitrary units (a.u.). Data are means ± SEM. No significant differences vs. healthy controls
were found in any of the conditions assayed. CYC, cyclophosphamide; dSSc, diffuse SSc; lSSc, limited SSc.
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Moreover, an early involvement of lymphatic vessels in
SSc may be suggested by the presence of puffy fingers,
which often precedes the onset of fibrosis [41].
Our data on significant reduction of fibrillin-1 deposi-
tion by B-MVECs cultured with SSc sera are in agreement
with previous findings on reduced fibrillin-1 in SSc skin
biopsies and fibroblast cultures [18,36]. The present find-
ings were revealed by using sera from both lSSc and dSSc
patients who were not under treatment with immunosup-
pressant or disease-modifying drugs. The fact that stimula-
tion of B-MVECs with sera from CYC-treated SSc
maintained normal fibrillin-1 deposition may suggest that
the immunosuppressive effect of CYC has a role in
redirection, through unknown mechanisms, of the deposi-
tion of fibrillin-1 in the ECM. It has been reported that
anti-fibrillin-1 antibodies are present in about 34% to 80%
of SSc patients and can exert profibrotic functions through
TGF-b-mediated mechanisms [21]. In the ECM, these
autoantibodies may interfere with the fibrillin-1-mediated
stabilization of latent TGF-b. Interestingly, CYC exerts its
anti-inflammatory and immunosuppressive functions
through direct cytoxicity of bone marrow precursors and
mature lymphocytes, with consequent reduction of B and
T cells [42]. Therefore, our findings might be explained by
the possible CYC-mediated reduction in circulating levels
of anti-fibrillin-1 autoantibodies and/or T-cell-derived
Figure 3 Expression of focal adhesion molecules in dermal blood microvascular endothelial cells and lymphatic microvascular
endothelial cells. Representative immunofluorescent images of focal adhesion molecules in blood microvascular endothelial cells (B-MVECs)
(A) and lymphatic microvascular endothelial cells (Ly-MVECs) (B) cultured with healthy sera are shown. Representative immunofluorescent
photomicrographs show double-labeling for avb3 integrin (green) (a), phosphorylated focal adhesion kinase (FAK) (red) (b) and a merged image
(c). Representative immunofluorescent photomicrographs show double-labeling for phalloidin (green) (d), vinculin (red) (e) and a merged image
(f). 4′,6-diamidino-2-phenylindole (DAPI)-stained nuclei are blue in merged images. In both B-MVECs and Ly-MVECs, avb3 integrin (a) and
phosphorylated FAK (b) are co-localized. avb3 integrin (a), phosphorylated FAK (b) and vinculin (e) are visible as small dots distributed all over
the cell surface. Phalloidin-stained actin filaments (d) are arranged in long strands running parallel to cell borders. Original magnification, ×40.
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proinflammatory molecules active on the endothelium.
However, we did not test the presence of such autoantibo-
dies or proinflammatory cytokines in our SSc serum sam-
ples. Further studies using specific blocking agents (for
example, anti-TGF-b antibodies or TGF-b receptor inhibi-
tors) or heat-inactivated serum samples will help to pro-
vide a mechanistic explanation for the differential serum
effects reported herein. Certainly, the observed effects of
CYC in our experimental conditions are not due to EC
proliferation, because fibrillin-1 deposition was evaluated
in postconfluent, quiescent EC cultures. Because of the
critical role of fibrillin-1 in sequestering latent TGF-b in
the ECM and in stabilizing blood vessel wall [6], a normal
deposition of fibrillin-1 by B-MVECs, as observed upon
challenge with CYC-treated SSc sera, might contribute
either indirectly to the control of fibroblast activation,
hence limiting fibrosis, or directly to microvascular dere-
modeling. In the present study, we focused on healthy der-
mal MVECs challenged with SSc sera. Further research is
required to investigate fibrillin-1 deposition by MVECs
isolated from the affected dermis of SSc patients. Indeed,
we cannot exclude the possibility that severely damaged
dermal MVECs, such as those of SSc patients, might be
less responsive to the beneficial effect of CYC, thus
Figure 4 Systemic sclerosis sera affect avb3 integrin and vinculin expression in dermal blood microvascular endothelial cells.
Quantification of avb3 integrin (A) and vinculin (B) in dermal blood microvascular endothelial cells (B-MVECs) challenged with systemic sclerosis
(SSc) and healthy control (CTR) sera. Data are means ± SEM of optical density in arbitrary units (a.u.). (A) The expression of avb3 integrin was
significantly lower in cells challenged with sera from naïve SSc patients (all naïve SSc, naïve limited SSc (lSSc) and naïve diffuse SSc (dSSc)) than
in cells treated with sera from healthy controls (**P < 0.001). No significant differences were found between cyclophosphamide (CYC)-treated SSc
patients (all SSc, lSSc and dSSc) and healthy controls, whereas expression of avb3 integrin in all CYC-treated SSc was significantly higher than
that in all naïve SSc (§P < 0.001). (B) The expression of vinculin was significantly higher in cells challenged with the sera of naïve dSSc than in
cells treated with sera from healthy controls (**P < 0.001). No significant differences were found in any of the other conditions tested.
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highlighting the necessity of an early diagnosis and start of
treatment.
We also investigated focal adhesion molecules and
observed a decreased avb3 integrin expression in
B-MVECs challenged with sera from treatment-naïve
SSc patients (both lSSc and dSSc). The discrepancy
between our results and those of other studies showing
an overexpression of avb3 integrins in fibroblasts iso-
lated from affected SSc skin may be due to the different
cell types employed (ECs vs. fibroblasts) [28]. In the
context of SSc, an overexpression of avb3 integrin in
fibroblasts, leading to increased production of collagen,
may be regarded as a negative event. Similarly, the
observed decreased levels of EC avb3 integrin expression
may also be interpreted as a negative event because
integrins are necessary for the normal interaction of ECs
with ECM proteins, particularly fibrillin, and hence for
fibrillin microfibril stabilization [43]. As observed for
fibrillin-1 deposition, the stimulation of B-MVECs with
CYC-treated SSc sera showed a potentially beneficial
effect by maintaining normal integrin avb3 expression.
Integrins are essential in triggering FAK phosphoryla-
tion, which in turn initiates a cascade that eventually
leads to cell adaptation to environmental stimuli [12].
However, the decrease in avb3 integrin expression fol-
lowing stimulation with naïve SSc sera, which we report
herein, was not associated with differences in FAK phos-
phorylation. Other integrins present on ECs, such as
a5b1 integrin, may account for avb3-independent activa-
tion of FAK [44]. Moreover, several molecules that sig-
nal through G protein-coupled receptors, including
neuropeptides, oncogenes, hormones and growth fac-
tors, present in patient’s serum might trigger integrin-
independent FAK phosphorylation [45,46].
We also observed increased vinculin expression in
B-MVECs challenged with sera from treatment-naïve
dSSc patients. This finding is in line with the previously
reported TGF-b-mediated increased production of vin-
culin-containing adhesion complexes in SSc myofibro-
blasts [47]. The increased vinculin-mediated adhesion to
the ECM has been proposed as a protective factor
against myofibroblast apoptosis, hence ultimately contri-
buting to fibrosis [47]. Because timely modulation of
expression and assembly of endothelial vinculin are cru-
cial during angiogenesis [48], dysregulated expression of
vinculin might have a role in the impaired angiogenic
process found in SSc [37]. The stimulation of B-MVECs
with sera from CYC-treated dSSc patients showed a
potentially beneficial effect by maintaining vinculin
expression at normal levels. This hypothesis is in agree-
ment with the previous evidence that CYC is able to
partially deremodel the damaged microvasculature in
SSc, as observed by nailfold videocapillaroscopy [49].
The observed significant increase in vinculin expression
in B-MVECs challenged with naïve dSSc sera, but not in
cells stimulated with lSSc sera, might be explained in
part by the fact that vinculin is one of the main proteins
affected by connective tissue growth factor [50], whose
serum levels are increased, especially in patients with
the diffuse form of the disease [51]. In contrast to the
findings obtained with B-MVECs, Ly-MVECs challenged
with SSc sera did not differ from healthy controls in the
expression of fibrillin-1 and any of the adhesion mole-
cules assayed. This difference may be due to the fact
that, under in vivo conditions, the lymphatic endothe-
lium is never directly exposed to the as yet undiscovered
serum factors that seem to affect the relationship
between B-MVECs and the surrounding ECM.
Conclusions
Our data clearly point to a possible role for a dysregu-
lated deposition of fibrillin-1 and expression of focal
adhesion molecules by dermal B-MVECs in SSc patho-
physiology. Moreover, for the first time, we have shown
that the beneficial effects of CYC treatment in SSc may
be due in part to the normalization of cell-matrix inter-
actions and fibrillin-1 deposition by B-MVECs.
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